This month, the Multiple Myeloma Hub is exploring the theme of high-risk multiple myeloma (MM). The first article on this subject dealt with what you need to know about high-risk MM, and can be found here.
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies…
During IWWM-12, the Lymphoma Hub was pleased to speak to Sæmundur Rögnvaldsson, University of Iceland, Reykjavik, IS. We asked about the iStopMM study and the…
To help navigate the exciting content being presented at the ASH Congress 2024, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the…
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence BCMA-directed therapies…
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies…
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies…
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies…
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies…
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies…
